Fasinumab - Mitsubishi Tanabe Pharma/Regeneron/Teva

Drug Profile

Fasinumab - Mitsubishi Tanabe Pharma/Regeneron/Teva

Alternative Names: MT-5547; REGN 475; SAR 164877

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Mitsubishi Tanabe Pharma Corporation; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Pain

Most Recent Events

  • 13 Apr 2018 Regeneron Pharmaceuticals plans the phase III FACT DEVICE trial for Pain (pain due to osteoarthritis of the knee or hip) in April 2018 (NCT03491904)
  • 05 Mar 2018 Phase-III clinical trials in Pain in Germany (SC) (EudraCT2017-001702-15)
  • 05 Mar 2018 Regeneron Pharmaceuticals initiates enrolment in the phase III FACT OA2 trial for Pain (due to osteoarthritis of knee or hip) in Denmark and Estonia (EudraCT2017-001702-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top